Is an ejection fraction of 20–25 % indicative of cardiomyopathy?

Is an Ejection Fraction of 20-25% Indicative of Cardiomyopathy?

Yes, an ejection fraction (EF) of 20-25% definitively indicates severe left ventricular systolic dysfunction and represents cardiomyopathy, regardless of the underlying etiology. This level of dysfunction falls well below the threshold of 40% that defines heart failure with reduced ejection fraction (HFrEF) in current guidelines 1, 2.

Defining the Severity

An EF of 20-25% represents severe systolic dysfunction by any standard:

• Normal EF is ≥50% 3
• HFrEF is defined as EF ≤40% 1, 2
• Your patient's EF of 20-25% is in the most severe category, placing them at substantially elevated risk for mortality and sudden cardiac death

The 2001 American Family Physician guideline explicitly states that classification and treatment recommendations are based on studies using ejection fractions of less than 40%, with patients having symptoms and an EF above 50% more likely having diastolic heart failure or noncardiac causes 1.

Clinical Implications of This Severe Dysfunction

Mortality Risk

Patients with EF ≤20% face particularly poor prognosis. Research demonstrates that 3-year mortality reaches 74% in patients with EF ≤20% 4. However, once EF drops below 20%, the absolute EF value itself becomes less predictive of mortality—instead, peak VO2 and hemodynamic response to therapy become the critical prognostic factors 5, 4.

The Critical Distinction: Etiology Matters for Treatment Planning

While the EF confirms cardiomyopathy, you must determine whether this is ischemic or non-ischemic because:

• Ischemic cardiomyopathy (from coronary artery disease) carries worse prognosis and may benefit from revascularization 6, 7
• Non-ischemic dilated cardiomyopathy has better potential for recovery with medical therapy 5, 8
• Specific cardiomyopathies (hypertrophic, restrictive, infiltrative like amyloid) require targeted therapies 9, 10, 6

The 2016 AHA Scientific Statement emphasizes that coronary artery disease is an independent risk factor for early mortality in patients with severely reduced EF 5.

Immediate Diagnostic Workup Required

Do not stop at the EF measurement. The 2016 AHA guidelines mandate a comprehensive evaluation to identify reversible or treatable causes 6:

Essential Initial Testing:

• Coronary evaluation (angiography or CT angiography) to exclude ischemic etiology
• Echocardiographic assessment of valve function, wall thickness, and filling patterns 2
• ECG looking for low voltage (suggests infiltrative disease), conduction abnormalities, or pseudo-infarct patterns 6, 11
• Laboratory workup: BNP/NT-proBNP, troponin, thyroid function, iron studies, serum protein electrophoresis (to screen for amyloid) 6

Red Flags Requiring Specialized Testing:

• Increased wall thickness with low voltage on ECG → Consider cardiac amyloidosis, obtain technetium-pyrophosphate scan 6, 11, 12
• History of hypertension → May represent reversible hypertensive cardiomyopathy 8
• Persistent tachycardia → Consider tachycardia-induced cardiomyopathy 13
• Family history of cardiomyopathy or sudden death → Genetic testing indicated 2, 6

Guideline-Directed Medical Therapy: Start Immediately

All four pillars of HFrEF therapy should be initiated rapidly, not sequentially 14:

1. ACE inhibitor/ARB or ARNI (sacubitril/valsartan preferred if tolerated) 15, 16
2. Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) 15, 17
3. Mineralocorticoid receptor antagonist (spironolactone or eplerenone) 15
4. SGLT2 inhibitor (dapagliflozin or empagliflozin) 14

The 2025 Swedish Heart Failure Registry analysis revealed that only 26-30% of patients receive SGLT2 inhibitors within the first year, representing a major treatment gap 14.

Hemodynamic Optimization is Critical

In patients with EF ≤20%, achieving pulmonary capillary wedge pressure ≤16 mmHg predicts 83% one-year survival versus 38% in those with persistently elevated pressures 5. This requires aggressive diuretic therapy and often inpatient hemodynamic monitoring.

Device Therapy Considerations

ICD for Primary Prevention

Refer for ICD evaluation once the patient is on optimal medical therapy for at least 3 months and EF remains ≤35% 16, 18:

• Class I indication for ischemic cardiomyopathy with EF ≤30% at least 40 days post-MI 16
• Class IIa indication for non-ischemic cardiomyopathy with EF ≤30% present for ≥9 months 16
• EF 31-35% represents Class IIb indication for non-ischemic etiology 16

Research shows that patients with non-ischemic cardiomyopathy have lower arrhythmic event rates (30% at 5 years for primary prevention) compared to ischemic patients 19.

CRT Consideration

If QRS duration ≥150 ms with LBBB morphology and NYHA class II-IV symptoms persist despite medical therapy, cardiac resynchronization therapy improves outcomes 16, 10.

Potential for Recovery

Do not assume EF of 20-25% is irreversible. The potential for improvement depends heavily on etiology:

• Hypertensive cardiomyopathy: Can recover to EF >50% with blood pressure control 8
• Tachycardia-induced: Often normalizes with rate control 13
• Non-ischemic dilated cardiomyopathy: Mean LVEF improvement of 10% is typical with optimal therapy 19
• Ischemic cardiomyopathy with viable myocardium: May improve with revascularization 7

The 2012 study demonstrated that hypertensive cardiomyopathy with severe LV dysfunction improved to mean EF of 52% over 574 days with appropriate therapy 8.

When to Consider Advanced Therapies

Refer for transplant evaluation if 10, 6:

• Persistent NYHA class III-IV symptoms despite optimal medical therapy for 3+ months
• Recurrent hospitalizations
• Peak VO2 <12-14 mL/kg/min on cardiopulmonary exercise testing
• Inability to achieve adequate hemodynamic control (wedge pressure >16 mmHg)
• Presence of ischemic etiology with persistently elevated filling pressures (21% one-year survival) 5

Common Pitfalls to Avoid

1. Assuming all severe LV dysfunction is "dilated cardiomyopathy" without excluding ischemic disease, infiltrative processes, or reversible causes
2. Delaying device therapy while waiting for "maximal medical optimization"—3 months on stable therapy is sufficient
3. Underutilizing SGLT2 inhibitors in the early treatment phase 14
4. Missing cardiac amyloidosis in older patients with HFpEF phenotype who actually have ATTR-CM with reduced EF 11, 12
5. Focusing solely on EF rather than hemodynamic parameters and functional capacity for prognostication in very low EF patients 5, 4